*ST长药：公司股票可能被实施财务类强制退市、重大违法强制退市或交易类强制退市。公司2024年度期末净资产为负，若2025年度期末净资产仍为负值，或财务报告被出具保留意见等审计报告，将触及财务类强制退市情形。此外，公司因涉嫌定期报告财务数据虚假记载被立案调查，可能触及重大违法强制退市情形。同时，公司股票收盘价连续低于1元，可能被实施交易类强制退市。公司还面临诉讼、仲裁案件风险、大额有息负债逾期风险、账户冻结风险及大额欠税风险。 百花医药：控股股东、实际控制人米在齐、米恩华、杨小玲终止筹划控制权变更事项，公司股票将于2026年1月7日复牌。由于公司控股股东、实际控制人与交易对方未就控制权变更相关重大事项达成一致意见，故决定终止本次控制权变更事项。 海思科：子公司四川海思科制药有限公司于2026年1月6日收到国家药品监督管理局下发的《受理通知书》，该通知书涉及药品HSK39297片的上市许可申请。HSK39297是一种高效的选择性补体B因子小分子抑制剂，适用于治疗既往未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（PNH）成人患者。临床研究显示，HSK39297在改善贫血、减少输血需求和

整理：肿瘤资讯来源：肿瘤资讯岁律更始，华章新启。2025年12月27日，中国临床肿瘤学会青年专家委员会（CSCO YOUNG）年终会于申城盛大启幕。本次会议由复旦大学附属肿瘤医院王碧芸教授担任大会主席，诚邀国内肿瘤诊疗领域的学术大咖与中青年骨干共赴华章。这不仅是一场年度学术成果的集中阅兵，更是一场立足当下、前瞻未来的高维对话，智慧火花与创新视野深度交融，为中国肿瘤防治事业的高质量发展擘画出宏伟蓝图。高屋建瓴：溯往思来，共策传承与远景会议伊始，王碧芸教授发表了热情洋溢的开幕致辞。王教授首先回顾了青委三年来的砥砺历程，感慨在后疫情时代，线下相聚与面对面学术碰撞显得愈发弥足珍贵。她对与会专家致以诚挚感谢，并强调本次年终盛会不仅是学术成果的年度盘点，更是传递人文温度、共叙同道情谊的温馨时刻。最后，王教授预祝大会圆满成功，期冀青委继续在医学创新的征途中并肩前行。Session1  领航之音主持：王碧芸教授、南京金陵医院龚新雷教授王碧芸教授首先为大家系统梳理了YOUNG研究乳腺癌系列的发展历程。自2018年启航以来，该系列研究始终秉持多中心、多学科深度协作的理念，实现了从真实世界回顾性研究向高质量

PALO ALTO, Calif., Jan. 6, 2026 /PRNewswire/ -- Segmed, Inc., a leader in real world medical imaging data for research and AI development, today announced that it has secured an independent Expert Determination confirming that its structured clinical data, medical imaging pixels, and radiology text meet the HIPAA de-identification standard. Continue Reading A unified de-identification pipeline for clinical data and medical imaging — HIPAA compliant by design. Expert Determination is one of the t

The Fund Will be Managed by Experienced Life Sciences Investor Nishant Rastogi NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the formation of a new philanthropic venture fund Lupus Ventures. The Fund is dedicated to advancing treatments and diagnostics for systemic lupus erythematosus (SLE), its manifestations, and related autoimmune conditions. Continue Reading Lupus Ventures aims to accelerate the deve

Groundbreaking code will facilitate use, adoption, and pathway for reimbursement of AI-based hemodynamic assessment, including Sensydia's Cardiac Performance System (CPS™). LOS ANGELES, Jan. 6, 2026 /PRNewswire/ -- Sensydia, a medical technology company advancing non-invasive cardiac assessment, today announced that the American Medical Association (AMA) has published a new industry-first Category III CPT® code, 1036T, for noninvasive augmentative AI hemodynamic assessment, encompassing Sensydia

– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is currently under FDA review – – Assay upgrades led to improved detection rates, limit of detection and signal-to-noise ratio – BRISBANE, Calif., Jan. 6, 2026 /PRNewswire/ -- Freenome, an early cancer detection company developing blood-based screening tests, today is reporting the improved clinical pe

Partnership focuses on delivering high-quality medical education to improve rare disease patient outcomes BOSTON and WASHINGTON, Jan. 6, 2026 /PRNewswire/ -- Medlive is proud to announce that the National Organization for Rare Disorders has again selected the company as its official Continuing Medical Education (CME) partner. This renewed commitment reflects the organizations' shared mission to expand access to rare disease education, equip clinicians with the tools to shorten time to diagnosis

TOKYO, Jan. 6, 2026 /PRNewswire/ -- Yonalink and PSP today announced a strategic collaboration aimed at simplifying the integration of medical information stored in Electronic Health Records (EHRs) into Electronic Data Capture (EDC) systems used in clinical trials. This initiative is designed to enhance operational efficiency and expand opportunities for global clinical trials conducted in Japan. PSP will leverage its advanced medical information management technologies developed through its clo

EDINBURGH, Scotland, TORONTO and EDMONTON, AB, Jan. 6, 2026 /PRNewswire/ -- Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals are pleased to announce they are receiving advisory services and funding from the competitive, transatlantic, UKRI Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) collaborative innovation program. This supports strategic partnership to develop next-generation therapeutics by combining the Chro

New Lenses Combine Advanced Silicone Hydrogel Material with Proven ActivControl® Technology*1 to Slow the Worsening of Myopia in Children†2,3 FAREHAM, England, Jan. 6, 2026 /PRNewswire/ -- CooperVision today announced the forthcoming launch of MyDay® MiSight® 1 day contact lenses in the UK and select European and surrounding markets, expanding its evidence-based myopia management portfolio. This new myopia control soft contact lens combines the proven MiSight® 1 day ActivControl® Technology with